Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
This distinction between true value and value traps can challenge even the most skilled investors. Luckily for you, we started StockStory to help you uncover exceptional companies. Keeping that in mind, here are two value stocks with strong fundamentals and one with little support.
One Value Stock to Sell:
Wyndham (WH)
Forward P/E Ratio: 14x
Established in 1981, Wyndham (NYSE:WH) is a global hotel franchising company with over 9,000 hotels across nearly 95 countries on six continents.
Why Should You Sell WH?
- Weak revenue per room over the past two years indicates challenges in maintaining pricing power and occupancy rates
- Underwhelming 11.9% return on capital reflects management’s difficulties in finding profitable growth opportunities, and its decreasing returns suggest its historical profit centers are aging
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
Wyndham is trading at $67.57 per share, or 14x forward P/E. Dive into our free research report to see why there are better opportunities than WH.
Two Value Stocks to Watch:
Boston Scientific (BSX)
Forward P/E Ratio: 13.3x
Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE:BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.
Why Are We Positive on BSX?
- Existing business lines can expand without risky acquisitions as its organic revenue growth averaged 15.8% over the past two years
- Additional sales over the last five years increased its profitability as the 18.6% annual growth in its earnings per share outpaced its revenue
- Free cash flow margin increased by 12.3 percentage points over the last five years, giving the company more capital to invest or return to shareholders
At $43.65 per share, Boston Scientific trades at 13.3x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.
California Resources (CRC)
Forward P/E Ratio: 12.9x
Operating some of California's most productive oil fields including Elk Hills and Belridge, California Resources (NYSE:CRC) explores for and produces crude oil, natural gas, and natural gas liquids from fields across California.
Why Are We Fans of CRC?
- Impressive 7.4% annual revenue growth over the last ten years indicates it’s winning market share this cycle
- Superiority of its unit economics is reflected in its stellar gross margin of 57.5%
- Strong free cash flow margin of 12.7% enables it to reinvest or return capital consistently
California Resources’s stock price of $52.75 implies a valuation ratio of 12.9x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.